Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the cancers with poorest prognosis, presenting a...
Saved in:
Main Authors: | Rita Rebelo (Author), Bárbara Polónia (Author), Lúcio Lara Santos (Author), M. Helena Vasconcelos (Author), Cristina P. R. Xavier (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma
by: Ningna Weng, et al.
Published: (2022) -
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
Published: (2021) -
Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities
by: Julie Dardare, et al.
Published: (2021) -
Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
by: Alexander G. Raufi, et al.
Published: (2021) -
Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma
by: Norihiro Sato, et al.
Published: (2016)